DO K-RAS MUTATION STATUS AND ANTI-TUMORAL THERAPIES INFLUENCE THE RISK OF SEMS-RELATED COMPLICATIONS IN PATIENTS WITH OBSTRUCTIVE COLORECTAL CANCER?